ARIADNERecruiting

An observational study of the already approved drug zanubrutinib in the treatment of various blood cancers, to gather more data on the tolerability and safety of the therapy

Gender
Women and men
Age
18 years and older
Trial type
Observational
Line of therapy
First line
Phase
Phase IV

What is this trial about?

is an already approved drug that can be used to treat patients with (WM), , (MZL), or (FL). Since some of these conditions are very rare, there is not yet sufficient information on the use of this medication in clinical practice. The ARIADNE study is investigating how the treatment affects patients’ quality of life, including how often it requires inpatient care. Patients who are at least 18 years old and have one of the conditions listed above are eligible to participate in the study.

Detailed description

Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), and follicular lymphoma (FL) are different types of or that affect the immune system. These different diseases lead to the uncontrolled proliferation of certain white blood cells, called , which can result in symptoms such as , susceptibility to infection, and enlarged lymph nodes. The exact causes of these diseases are not fully understood, but genetic factors and immune system disorders play a role. Standard treatment for these diseases varies, but usually includes chemotherapy, , and, increasingly, so-called targeted therapies that target a specific functional mechanism in the affected cells. Zanubrutinib, a Bruton’s (BTK inhibitor), is a drug that specifically inhibits the activity of an enzyme necessary for the survival and growth of cancer cells. This drug is already approved for the diseases mentioned in the study.

The ARIADNE study is an that collects data under real-world conditions. The study is non-interventional (it does not prescribe any treatment). Patients will be followed for up to 5 years after the start of the study, with a focus on quality of life, the need to seek medical help for treatment-related issues (e.g., hospitalizations), and satisfaction with treatment. Patients are divided into groups based on their diagnosis and treated accordingly.

Eligible participants include women and men aged 18 and older who, depending on their clinical presentation, have not yet received prior treatment or who already require a second or third line of treatment. Patients with Waldenström macroglobulinemia or chronic lymphocytic leukemia may participate in all treatment phases; however, those with marginal zone lymphoma (MZL) or follicular lymphoma (FL) should be in the second (MZL) or third (FL) treatment phase, respectively. For MZL, prior treatment with an anti- antibody (e.g., ) is also required.

Facts

  1. Which disease: (WM), , (MZL), (FL).
  2. Cancer characteristics: untreated (WM, CLL) or previously treated (WM, CLL, MZL, FL).
  3. What the study investigates: An of (already approved) in the above-mentioned diseases.
  4. Study objective: To evaluate quality of life and adverse events (e.g., hospitalizations) associated with regular use of zanubrutinib.
  5. How long will the study last: Total duration of approximately 75 months.
  6. Study characteristics: Observational study, multiple treatment groups, open-label.

Trial sites

8 trial sites in Germany are listed. Find a site near you.

  • Klinikum St. Marien Amberg

    Mariahilfbergweg 7, 92224 Amberg, Oberpfalz

    Recruiting
  • Caritas-Krankenhaus Bad Mergentheim

    Uhlandstraße 7, 97980 Bad Mergentheim

    Recruiting
  • Klinikum Bayreuth GmbH

    Bayreuth

    Recruiting
  • Klinikum Fürth

    Jakob-Henle-Straße 1, 90766 Fürth, Bayern

    Recruiting
  • Lübecker Onkologische Schwerpunktpraxis

    23562 Lübeck

    Recruiting
  • Hämatologisch-Onkologische Schwerpunktpraxis in Würzburg & Kitzingen

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.